Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 33 (2010), Issue 2, Pages 55-59
http://dx.doi.org/10.3233/ACP-CLO-2010-0534

Activating Mutation (V617F) in the Tyrosine Kinase JAK2 is Absent in Locally-Confined or Castration-Resistant Prostate Cancer

Lei Gu,1 Xian-Hua Zhu,2 Tapio Visakorpi,3 Kalle Alanen,4 Tuomas Mirtti,4 Tina Bocker Edmonston,2 and Marja T. Nevalainen1,5,6

1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
2Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA
3Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
4Department of Pathology, Institute of Biomedicine, University of Turku, Turku, Finland
5Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA
6Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA

Copyright © 2010 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Transcription factor Stat5a/b is highly critical for the viability of human prostate cancer cells in vitro and for prostate tumor growth in vivo. Stat5 is constitutively active in clinical prostate cancers but not in the normal human prostate epithelium. Moreover, Stat5a/b activation in prostate cancer is associated with high histological grade of prostate cancer. However, the molecular mechanisms underlying constitutive activation of Stat5a/b in prostate cancer are unclear. The receptor-associated tyrosine kinase Jak2 is a known key activator of Stat5a/b in prostate cancer cells in response to ligand stimulation. Recently, a single gain-of-function point mutation of JAK2 was described in myeloproliferative diseases leading to constitutive Jak2 kinase activity, subsequent Stat5a/b activation and involvement of V617F Jak2 in the pathogenesis of myeloproliferative disorders.

Materials and Methods: We determined whether JAK2 undergoes the V617F activating mutation during clinical progression of human prostate cancer using a highly sensitive assay (amplification refractory mutation system) and a unique material of fresh specimens from organ-confined or castration-resistant prostate cancers.

Results: The JAK2 V617F mutation was not found in any of the normal or malignant prostate samples analyzed in this study.

Conclusions: Future work should focus on determining the molecular mechanisms other than V617F mutation of Jak2 resulting in continuous Stat5 activation in clinical prostate cancers.